Ingredients

Alcami in API Manufacturing Pact with Solasia

November 13, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

Alcami will manufacture clinical supply of the API for a drug candidate targeting various hematologics and solid cancers.

Awards Recognize Industry Contributions

November 02, 2017

Industry experts were honored for business, scientific, and social contributions.

Growing Demand for Taste-Masking Technologies

November 02, 2017

Taste masking increases drug acceptability and medication adherence in pediatric, geriatric, and other special patient populations.

PTSM: Pharmaceutical Technology Sourcing and Management

Setting Safety Processes for Potentially Potent APIs

November 01, 2017

CDMOs sharpen skills for identifying API potency risks and establishing safety and handling procedures.

AbbVie and Alector Partner on Alzheimer’s Disease Immunotherapies

October 27, 2017

AbbVie will pay a $205-million upfront payment and have the option to develop and commercialize two antibody targets globally.

FDA Approves Kite’s CAR-T Drug, Second Gene-Therapy in US

October 20, 2017

This approval marks the second gene therapy to be approved by FDA and the first to be approved for certain types of non-Hodgkin lymphoma.

Lilly and CureVac Partner on mRNA Cancer Vaccines in $1.8-Billion Deal

October 20, 2017

The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.

CordenPharma Invests in Small Molecule API Development Capacity

October 17, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

CordenPharma will expand development capacity for small molecules, peptides, and carbohydrates at its Liestal, Switzerland site

FDA Expands Approval for J&J’s Psoriasis Biologic

October 16, 2017

Stelara (ustekinumab), already approved for treating adults, is now also approved for treating adolescents with moderate to severe plaque psoriasis.

GSK’s Shingles Vaccine Approved in Canada

October 16, 2017

The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.